Business Context and Reporting Period
Company: Codexis, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 5, 2016
Event: Completion of the second and final phase in the transfer of the proprietary CodeEvolver protein engineering platform technology to Merck (MSD).
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the finalization of the technology transfer agreement with Merck. This event marks the conclusion of the transfer process for the CodeEvolver platform.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) for full details regarding the announcement but does not include specific forward-looking guidance, risk factors, or contingencies within the body of this 8-K text.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific financial terms or milestones associated with the Merck technology transfer.
- Verify the impact of the completed technology transfer on future revenue recognition or licensing agreements.
- Check subsequent filings for any financial implications resulting from this finalized transfer.